NCT01733394 Equivalence Among Antiepileptic Drug Generic and Brand Products in People With Epilepsy: Single-Dose 6-Period Replicate Design (EQUIGEN Single-Dose Study) Status COMPLETED Phase PHASE4
NCT01730170 Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD) Status COMPLETED Phase N/A
NCT01728077 Evaluation of Long-term Safety, and Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects With Epilepsy Status COMPLETED Phase PHASE3
NCT01713777 Equivalence Among Antiepileptic Drug Generic and Brand Products in People With Epilepsy: Chronic-Dose 4-Period Replicate Design Status COMPLETED Phase PHASE4
NCT01710657 A Trial to Evaluate the Efficacy and Safety of Adjunctive Therapy With Lacosamide in Adults With Partial-Onset Seizures Status COMPLETED Phase PHASE3
NCT01703143 Pilot Study to Evaluate MR-guided Laser Ablation of Focal Lesions in Patients With Medically Refractory Partial Epilepsy Status COMPLETED Phase PHASE1
NCT01689649 A Study to Assess Tolerability and Efficacy of Topiramate Monotherapy in Recently Diagnosed Patients With Epilepsy Status COMPLETED Phase PHASE4
NCT01682681 An Observational Study to Evaluate Long-term Retention Rate of Topiramate in Participants With Epilepsy Status COMPLETED Phase N/A
NCT01679002 Steady-state Pharmacokinetics of BIA 2-093 and Oxcarbazepine in Healthy Volunteers Status COMPLETED Phase PHASE1
NCT01678976 Tolerability and Pharmacokinetics of a Single 900 mg Oral Dose of BIA 2-093 and Oxcarbazepine in Healthy Volunteers Status COMPLETED Phase PHASE1
NCT01668654 Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS Status TERMINATED Phase PHASE3
NCT01660672 Enteral Levetiracetam For Seizure Control In Pediatric Cerebral Malaria Status COMPLETED Phase PHASE1/PHASE2
NCT01657084 Stopping and Preventing Epileptic Seizures Using a Partial Rebreathing Mask Status COMPLETED Phase NA
NCT01653262 Effect of Brivaracetam (BRV) on Nonpsychotic Behavioral Side Effects in Subjects Treated Previously With Levetiracetam (LEV) Status COMPLETED Phase PHASE3
NCT01648101 Assessment of the Efficacy and Safety of 2 Doses of Retigabine Immediate Release (900 mg/Day and 600 mg/Day) Used as Adjunctive Therapy in Adult Asian Subjects With Drug-resistant Partial-onset Seizures Status TERMINATED Phase PHASE3
NCT01627860 First Add-on vs. Mono-therapy Study of Topiramate in Neuro-Surgical Patients Status COMPLETED Phase PHASE4
NCT01626599 Study to Evaluate a New Device Designed to Collect Heart Activity and Body Movement Data Status COMPLETED Phase NA